More time without cancer returning: personalised vaccine cut melanoma recurrence risk by 42% in a large trial
A personalised mRNA cancer vaccine developed by Moderna and Merck reduced melanoma recurrence risk by 42% compared with standard treatment in a large clinical trial. Patients lived significantly longer without their cancer returning, a result oncologists described as an important advance.
Source: statnews.com
Read the original story →